{ "api_version": "1", "request": { "url": "https://clinicaltrialsfind.com/api/v1/search.json?condition=Aggressive+NHL&page=2", "query": { "condition": "Aggressive NHL", "page": 2 }, "page_size": 10 }, "pagination": { "page": 2, "page_size": 10, "total_count": 10, "total_pages": 1, "next_page_url": null, "previous_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?condition=Aggressive+NHL&page=1&page_size=10" }, "source": "remote", "last_synced_at": "2026-05-22T07:48:26.983Z", "attribution": "Data derived from public ClinicalTrials.gov records. The official record at https://clinicaltrials.gov/ remains the source of truth for current availability, contacts, and full study details.", "notes": [ "This endpoint exposes only public summary fields — no participant contact emails, phone numbers, or scraped investigator contact details.", "For contact information and full protocol detail, follow each trial's `official_url` to the ClinicalTrials.gov record.", "This API is a navigational aid. It does not provide medical advice, eligibility determinations, or compensation guarantees." ], "trials": [ { "nct_id": "NCT05171647", "title": "A Study Evaluating Efficacy and Safety of Mosunetuzumab in Combination With Polatuzumab Vedotin Compared to Rituximab in Combination With Gemcitabine Plus Oxaliplatin in Participants With Relapsed or Refractory Aggressive B-Cell Non-Hodgkin's Lymphoma", "overall_status": "ACTIVE_NOT_RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "PHASE3" ], "conditions": [ "Non-Hodgkin Lymphoma" ], "interventions": [ { "name": "Mosunetuzumab", "type": "DRUG" }, { "name": "Polatuzumab vedotin", "type": "DRUG" }, { "name": "Tocilizumab", "type": "DRUG" }, { "name": "Rituximab", "type": "DRUG" }, { "name": "Gemcitabine", "type": "DRUG" }, { "name": "Oxaliplatin", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Hoffmann-La Roche", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 208, "start_date": "2022-04-25", "completion_date": "2027-02-28", "has_results": true, "last_update_posted_date": "2026-05-07", "last_synced_at": "2026-05-22T07:48:26.983Z", "location_count": 4, "location_summary": "Duarte, California • Chesterfield, Missouri • Austin, Texas + 1 more", "locations": [ { "city": "Duarte", "state": "California" }, { "city": "Chesterfield", "state": "Missouri" }, { "city": "Austin", "state": "Texas" }, { "city": "Houston", "state": "Texas" } ], "official_url": "https://clinicaltrials.gov/study/NCT05171647" }, { "nct_id": "NCT05665530", "title": "A Study of PRT2527 as Monotherapy and in Combination With Zanubrutinib or Venetoclax in Participants With R/R Hematologic Malignancies", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1" ], "conditions": [ "Aggressive B-Cell Non-Hodgkin's Lymphoma (NHL)", "Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma (CLL/SLL)", "Mantle Cell Lymphoma (MCL)", "Richter's Syndrome", "T-cell Lymphoma", "Diffuse Large B-cell Lymphoma (DLBCL)", "Marginal Zone Lymphoma", "Myeloid Malignancies", "Acute Myeloid Leukemia (AML)", "Chronic Myelomonocytic Leukemia (CMML)", "Myelodysplastic Syndrome (MDS)", "MDS/Myeloproliferative Neoplasm (MPN) Overlap Syndrome" ], "interventions": [ { "name": "PRT2527", "type": "DRUG" }, { "name": "Zanubrutinib", "type": "DRUG" }, { "name": "Venetoclax", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Prelude Therapeutics", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 86, "start_date": "2023-09-12", "completion_date": "2026-01-21", "has_results": false, "last_update_posted_date": "2026-01-26", "last_synced_at": "2026-05-22T07:48:26.983Z", "location_count": 5, "location_summary": "Duarte, California • Bethesda, Maryland • Boston, Massachusetts + 2 more", "locations": [ { "city": "Duarte", "state": "California" }, { "city": "Bethesda", "state": "Maryland" }, { "city": "Boston", "state": "Massachusetts" }, { "city": "New York", "state": "New York" }, { "city": "Charlottesville", "state": "Virginia" } ], "official_url": "https://clinicaltrials.gov/study/NCT05665530" }, { "nct_id": "NCT06173518", "title": "A Study of CD19 Targeted CAR T Cell Therapy in Pediatric Patients With Relapsed or Refractory B Cell Acute Lymphoblastic Leukemia (B ALL) and Aggressive Mature B-cell Non-Hodgkin Lymphoma (B NHL)", "overall_status": "RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1" ], "conditions": [ "Relapsed or Refractory B Cell Acute Lymphoblastic Leukemia", "Relapsed or Refractory B Cell Non-Hodgkin Lymphoma" ], "interventions": [ { "name": "AUTO1", "type": "BIOLOGICAL" } ], "intervention_types": [ "BIOLOGICAL" ], "sponsor": "Autolus Limited", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "0 Years", "maximum_age": "18 Years", "sex": "ALL", "summary": "0 Years to 18 Years" }, "enrollment_count": 30, "start_date": "2023-11-16", "completion_date": "2027-11", "has_results": false, "last_update_posted_date": "2026-03-02", "last_synced_at": "2026-05-22T07:48:26.983Z", "location_count": 3, "location_summary": "Philadelphia, Pennsylvania • San Antonio, Texas • Salt Lake City, Utah", "locations": [ { "city": "Philadelphia", "state": "Pennsylvania" }, { "city": "San Antonio", "state": "Texas" }, { "city": "Salt Lake City", "state": "Utah" } ], "official_url": "https://clinicaltrials.gov/study/NCT06173518" }, { "nct_id": "NCT06806033", "title": "A Study to Evaluate the Optimization of the Cytokine Release Syndrome Profile for Glofitamab in Combination With Gemcitabine Plus Oxaliplatin in Participants With Relapsed/Refractory Aggressive B-Cell Non-Hodgkin's Lymphoma", "overall_status": "RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "B-Cell Non-Hodgkins Lymphoma" ], "interventions": [ { "name": "Obinutuzumab", "type": "DRUG" }, { "name": "Glofitamab", "type": "DRUG" }, { "name": "Gemcitabine", "type": "DRUG" }, { "name": "Oxaliplatin", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Hoffmann-La Roche", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 100, "start_date": "2025-03-05", "completion_date": "2029-03-30", "has_results": false, "last_update_posted_date": "2026-04-27", "last_synced_at": "2026-05-22T07:48:26.983Z", "location_count": 32, "location_summary": "Anchorage, Alaska • Clovis, California • Fullerton, California + 28 more", "locations": [ { "city": "Anchorage", "state": "Alaska" }, { "city": "Clovis", "state": "California" }, { "city": "Fullerton", "state": "California" }, { "city": "Glendale", "state": "California" }, { "city": "Los Angeles", "state": "California" } ], "official_url": "https://clinicaltrials.gov/study/NCT06806033" }, { "nct_id": "NCT03749018", "title": "Nivolumab With DA-REPOCH Chemotherapy Regimen in Treating Patients With Aggressive B-Cell Non-Hodgkin's Lymphoma", "overall_status": "ACTIVE_NOT_RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Aggressive Non-Hodgkin Lymphoma", "Ann Arbor Stage I Primary Mediastinal (Thymic) Large B-Cell Cell Lymphoma", "Ann Arbor Stage II B-Cell Non-Hodgkin Lymphoma", "Ann Arbor Stage II Primary Mediastinal (Thymic) Large B-Cell Cell Lymphoma", "Ann Arbor Stage III B-Cell Non-Hodgkin Lymphoma", "Ann Arbor Stage III Primary Mediastinal (Thymic) Large B-Cell Cell Lymphoma", "Ann Arbor Stage IV B-Cell Non-Hodgkin Lymphoma", "Ann Arbor Stage IV Primary Mediastinal (Thymic) Large B-Cell Cell Lymphoma", "Diffuse Large B-Cell Lymphoma", "High Grade B-Cell Lymphoma With MYC and BCL2 and/or BCL6 Rearrangements", "High Grade B-Cell Lymphoma, Not Otherwise Specified", "Indolent Non-Hodgkin Lymphoma", "Mediastinal B-Cell Lymphoma, Unclassifiable, With Features Intermediate Between Diffuse Large B-Cell Lymphoma and Classic Hodgkin Lymphoma", "Transformed Non-Hodgkin Lymphoma" ], "interventions": [ { "name": "Cyclophosphamide", "type": "DRUG" }, { "name": "Doxorubicin Hydrochloride", "type": "DRUG" }, { "name": "Etoposide", "type": "DRUG" }, { "name": "Nivolumab", "type": "BIOLOGICAL" }, { "name": "Prednisone", "type": "DRUG" }, { "name": "Rituximab", "type": "BIOLOGICAL" }, { "name": "Vincristine Sulfate", "type": "DRUG" } ], "intervention_types": [ "DRUG", "BIOLOGICAL" ], "sponsor": "David Bond, MD", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 30, "start_date": "2019-01-02", "completion_date": "2026-12-31", "has_results": false, "last_update_posted_date": "2026-02-06", "last_synced_at": "2026-05-22T07:48:26.983Z", "location_count": 1, "location_summary": "Columbus, Ohio", "locations": [ { "city": "Columbus", "state": "Ohio" } ], "official_url": "https://clinicaltrials.gov/study/NCT03749018" }, { "nct_id": "NCT05583149", "title": "Acalabrutinib + Liso-Cel In R/R Aggressive B-Cell Lymphomas", "overall_status": "ACTIVE_NOT_RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Refractory Aggressive B-cell Lymphomas", "Refractory B-Cell Non-Hodgkin Lymphoma", "Aggressive B-cell NHL", "Diffuse Large B-cell Lymphoma (DLBCL)", "De Novo or Transformed Indolent B-cell Lymphoma", "DLBCL, Nos Genetic Subtypes", "T Cell/Histiocyte-rich Large B-cell Lymphoma", "EBV-Positive DLBCL, Nos", "Primary Mediastinal [Thymic] Large B-cell Lymphoma (PMBCL)", "High-Grade B-Cell Lymphoma, Nos", "C-MYC/BCL6 Double-Hit High-Grade B-Cell Lymphoma", "Grade 3b Follicular Lymphoma", "C-MYC/BCL2 Double-Hit High-Grade B-Cell Lymphoma" ], "interventions": [ { "name": "ACALABRUTINIB", "type": "DRUG" }, { "name": "LISOCABTAGENE MARALEUCEL", "type": "DRUG" }, { "name": "Lymphodepleting chemotherapy", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Patrick C. Johnson, MD", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 28, "start_date": "2023-03-01", "completion_date": "2029-03-01", "has_results": true, "last_update_posted_date": "2026-01-29", "last_synced_at": "2026-05-22T07:48:26.983Z", "location_count": 2, "location_summary": "Boston, Massachusetts", "locations": [ { "city": "Boston", "state": "Massachusetts" }, { "city": "Boston", "state": "Massachusetts" } ], "official_url": "https://clinicaltrials.gov/study/NCT05583149" }, { "nct_id": "NCT01193842", "title": "Vorinostat and Combination Chemotherapy With Rituximab in Treating Patients With HIV-Related Diffuse Large B-Cell Non-Hodgkin Lymphoma or Other Aggressive B-Cell Lymphomas", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1", "PHASE2" ], "conditions": [ "AIDS-Related Plasmablastic Lymphoma", "AIDS-Related Primary Effusion Lymphoma", "Ann Arbor Stage I Diffuse Large B-Cell Lymphoma", "Ann Arbor Stage I Grade 3 Follicular Lymphoma", "Ann Arbor Stage II Diffuse Large B-Cell Lymphoma", "Ann Arbor Stage II Grade 3 Contiguous Follicular Lymphoma", "Ann Arbor Stage II Grade 3 Non-Contiguous Follicular Lymphoma", "Ann Arbor Stage III Diffuse Large B-Cell Lymphoma", "Ann Arbor Stage III Grade 3 Follicular Lymphoma", "Ann Arbor Stage IV Diffuse Large B-Cell Lymphoma", "Ann Arbor Stage IV Grade 3 Follicular Lymphoma", "HIV Infection", "Plasmablastic Lymphoma", "Primary Effusion Lymphoma", "Recurrent Diffuse Large B-Cell Lymphoma", "Recurrent Grade 3 Follicular Lymphoma" ], "interventions": [ { "name": "Cyclophosphamide", "type": "DRUG" }, { "name": "Doxorubicin Hydrochloride", "type": "DRUG" }, { "name": "Etoposide", "type": "DRUG" }, { "name": "Laboratory Biomarker Analysis", "type": "OTHER" }, { "name": "Pharmacological Study", "type": "OTHER" }, { "name": "Prednisone", "type": "DRUG" }, { "name": "Rituximab", "type": "BIOLOGICAL" }, { "name": "Vincristine Sulfate", "type": "DRUG" }, { "name": "Vorinostat", "type": "DRUG" } ], "intervention_types": [ "DRUG", "OTHER", "BIOLOGICAL" ], "sponsor": "National Cancer Institute (NCI)", "sponsor_class": "NIH", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 107, "start_date": "2010-10-06", "completion_date": "2022-05-19", "has_results": true, "last_update_posted_date": "2023-11-21", "last_synced_at": "2026-05-22T07:48:26.983Z", "location_count": 35, "location_summary": "Montgomery, Alabama • La Jolla, California • Los Angeles, California + 16 more", "locations": [ { "city": "Montgomery", "state": "Alabama" }, { "city": "La Jolla", "state": "California" }, { "city": "Los Angeles", "state": "California" }, { "city": "Los Angeles", "state": "California" }, { "city": "San Diego", "state": "California" } ], "official_url": "https://clinicaltrials.gov/study/NCT01193842" }, { "nct_id": "NCT00588094", "title": "Dose Augmented Rituximab and ICE for Pts With Primary Refractory and Poor Risk Relapsed Aggressive B-Cell NHL", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Lymphoma", "B-cell Non-Hodgkin's Lymphoma" ], "interventions": [ { "name": "Rituximab, Ifosfamide, Carboplatin, VP-16, Mesna, G-CSF, Stem Cell Transplant", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Memorial Sloan Kettering Cancer Center", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": "72 Years", "sex": "ALL", "summary": "18 Years to 72 Years" }, "enrollment_count": 20, "start_date": "2003-10", "completion_date": "2010-03", "has_results": true, "last_update_posted_date": "2015-12-04", "last_synced_at": "2026-05-22T07:48:26.983Z", "location_count": 1, "location_summary": "New York, New York", "locations": [ { "city": "New York", "state": "New York" } ], "official_url": "https://clinicaltrials.gov/study/NCT00588094" }, { "nct_id": "NCT06238648", "title": "Epcoritamab Compared to Observation for Treating B-cell Lymphoma Patients Not in Complete Remission After CD19-directed CAR-T Therapy", "overall_status": "RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Diffuse Large B-Cell Lymphoma, Not Otherwise Specified", "Primary Mediastinal Large B-Cell Lymphoma", "Transformed Indolent B-Cell Non-Hodgkin Lymphoma to Diffuse Large B-Cell Lymphoma" ], "interventions": [ { "name": "Biopsy", "type": "PROCEDURE" }, { "name": "Biospecimen Collection", "type": "PROCEDURE" }, { "name": "Computed Tomography", "type": "PROCEDURE" }, { "name": "Epcoritamab", "type": "BIOLOGICAL" }, { "name": "Magnetic Resonance Imaging", "type": "PROCEDURE" }, { "name": "Patient Observation", "type": "OTHER" }, { "name": "Positron Emission Tomography", "type": "PROCEDURE" } ], "intervention_types": [ "PROCEDURE", "BIOLOGICAL", "OTHER" ], "sponsor": "Academic and Community Cancer Research United", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 120, "start_date": "2024-01-31", "completion_date": "2030-12-31", "has_results": false, "last_update_posted_date": "2024-09-26", "last_synced_at": "2026-05-22T07:48:26.983Z", "location_count": 6, "location_summary": "Rochester, Minnesota • St Louis, Missouri • Hackensack, New Jersey + 3 more", "locations": [ { "city": "Rochester", "state": "Minnesota" }, { "city": "St Louis", "state": "Missouri" }, { "city": "Hackensack", "state": "New Jersey" }, { "city": "New York", "state": "New York" }, { "city": "Chapel Hill", "state": "North Carolina" } ], "official_url": "https://clinicaltrials.gov/study/NCT06238648" }, { "nct_id": "NCT02348216", "title": "Study Evaluating the Safety and Efficacy of KTE-C19 in Adult Participants With Refractory Aggressive Non-Hodgkin Lymphoma", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1", "PHASE2" ], "conditions": [ "Refractory Diffuse Large B Cell Lymphoma (DLBCL)", "Relapsed Diffuse Large B-Cell Lymphoma", "Transformed Follicular Lymphoma (TFL)", "Primary Mediastinal B-cell Lymphoma (PMBCL)", "High Grade B-cell Lymphoma (HGBCL)" ], "interventions": [ { "name": "Axicabtagene Ciloleucel", "type": "BIOLOGICAL" }, { "name": "Fludarabine", "type": "DRUG" }, { "name": "Cyclophosphamide", "type": "DRUG" }, { "name": "Levetiracetam", "type": "DRUG" }, { "name": "Tocilizumab", "type": "DRUG" }, { "name": "Dexamethasone", "type": "DRUG" }, { "name": "High-dose methylprednisolone", "type": "DRUG" }, { "name": "Bendamustine", "type": "DRUG" }, { "name": "Rituximab", "type": "DRUG" }, { "name": "Doxorubicin", "type": "DRUG" }, { "name": "Prednisone", "type": "DRUG" }, { "name": "Vincristine", "type": "DRUG" }, { "name": "Ifosfamide", "type": "DRUG" }, { "name": "Carboplatin", "type": "DRUG" }, { "name": "Etoposide", "type": "DRUG" }, { "name": "Gemcitabine", "type": "DRUG" }, { "name": "Oxaliplatin", "type": "DRUG" }, { "name": "Cisplatin", "type": "DRUG" }, { "name": "Methylprednisolone", "type": "DRUG" } ], "intervention_types": [ "BIOLOGICAL", "DRUG" ], "sponsor": "Kite, A Gilead Company", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 307, "start_date": "2015-04-21", "completion_date": "2023-07-27", "has_results": true, "last_update_posted_date": "2024-06-04", "last_synced_at": "2026-05-22T07:48:26.983Z", "location_count": 23, "location_summary": "Gilbert, Arizona • Duarte, California • La Jolla, California + 19 more", "locations": [ { "city": "Gilbert", "state": "Arizona" }, { "city": "Duarte", "state": "California" }, { "city": "La Jolla", "state": "California" }, { "city": "Palo Alto", "state": "California" }, { "city": "Santa Monica", "state": "California" } ], "official_url": "https://clinicaltrials.gov/study/NCT02348216" } ] }